Zobrazeno 1 - 3
of 3
pro vyhledávání: '"V. V. Vasilovskiy"'
Autor:
V. A. Yavorskaya, N. P. Voloshina, V. V. Khvysyuk, A. V. Grebenyuk, A. Yu. Gavryushin, K. V. Gretskych, O. L. Pelekhova, Yu. E. Mikulinsky, V. V. Vasilovskiy, L. F. Shestopalova, E. A. Shchegelskaya
Publikováno v:
Ukrainian Neurosurgical Journal, Iss 4, Pp 89-97 (2006)
The possibility of differentiation in vitro of mouse bone marrow stromal cells into progenitor of neuronal cells has been shown with condition of specific medias and some inductors using for cultivation.Reparation on tissue level was more active in m
Externí odkaz:
https://doaj.org/article/3eb38299a3894b8bb55e1d9890ff80f3
Autor:
D V Sazonov, L I Volkova, O P Patrusheva, L V Chichanovskaya, A V Zinkina-Orikhan, Kotov Sv, M A Sherman, M N Zakharova, T I Negrich, F. A. Khabirov, Yu V Trinitatskiy, L P Bosenko, A N Boyko, P. V. Timchenko, K B Tursunova, E V Parshina, M Ya Khavunka, Yu N Lin'kova, E V Lekomtseva, S. V. Prokopenko, V V Vasilovskiy
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 117(2. Vyp. 2)
To prove the equivalent efficacy of teberif (BCD-033, interferon beta-1) and rebif (interferon beta-1a) in patients with remitting multiple sclerosis (RMS).A multicenter double blind placebo-controlled comparative randomized III phase study included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93d0210c2394ef5581b6be0957c7270
https://pubmed.ncbi.nlm.nih.gov/28617368
https://pubmed.ncbi.nlm.nih.gov/28617368
Autor:
F. A. Khabirov, M Ya Khavunka, T I Negrich, E V Lekomtseva, Yu V Trinitatskiy, L I Volkova, S. V. Prokopenko, V V Vasilovskiy, E Yu Stukalina, D V Sazonov, O P Patrusheva, Kotov Sv, M A Sherman, A V Zinkina-Orikhan, L V Timchenko, E V Parshina, L P Bosenko, A N Boyko, L V Chichanovskaya, Yu N Lin'kova, M N Zakharova, I G Obukhova, Roman Ivanov
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 119:73
To evaluate efficacy, safety, and tolerability of the treatment with teberif/interferon β-1a, to analyze safety, tolerability and dynamics of key efficacy variables after switching from referent drug rebif to biosimilar teberif in patients with remi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46019bc35b7ad16dd208a674713fb402
https://doi.org/10.17116/jnevro20191192273
https://doi.org/10.17116/jnevro20191192273